As biotech executives look to get off the treadmill of financing their companies from milestone to milestone, at-the-market (ATM) offerings have become more popular. According to Brinson Patrick Securities Corp., use of ATM offerings by life sciences companies reached a record high in the third quarter. Read More
The FDA wants to hear from industry and other interested parties on what should constitute a "qualifying pathogen" that could trigger a range of incentives designed to encourage companies to develop new antibiotics targeting these designated pathogens. Read More
